about
sameAs
Identification of novel Smad2 and Smad3 associated proteins in response to TGF-beta1Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitroBRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionProtein arginine methyltransferase I: substrate specificity and role in hnRNP assemblyIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesDevelopment of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectivesMulti-perspective quality control of Illumina exome sequencing data using QC3.Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators.Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancerRNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.p63 and epithelial biology.p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network.Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis.The DNA binding activity of p53 displays reaction-diffusion kinetics.Subtyping of triple-negative breast cancer: implications for therapyThe Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutationsCell-cycle dysregulation and anticancer therapy.Combined modality management of breast cancer: development of predictive markers through proteomics.Detection of internal exon deletion with exon Del.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerp63: Molecular complexity in development and cancer.Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cellsTNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to AfatinibClinical implications of molecular heterogeneity in triple negative breast cancer.Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.Transcriptional programs regulated by p63 in normal epithelium and tumors.A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling.Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer
P50
Q24336739-D0B2A0B7-AC63-46C6-863E-9CEFA1127085Q24794867-7E175E74-D464-437F-B865-F255B32E00F9Q27852730-DA7DAE42-4A09-4996-9524-96A933EA9167Q28512345-2E88248F-DF54-465A-B456-0EBC2B82B1A9Q29617680-CC4364D1-FE36-4F81-B336-A9142946D652Q30275521-D9B48226-6801-4BD6-BF24-79DFA8CF9432Q30477571-2B2EC703-0650-4BD5-A140-71048D9E0F0AQ30583965-E5459A7D-DA2C-4D6C-AE0D-C40752ACC5AEQ30794236-DAC9271C-AEBD-4B6C-9EBB-B4D85AD71B83Q30985595-BD71FC5B-A510-4AA9-9764-FF87BDD87907Q33226324-3EC54B7E-580E-402A-8959-5B9A74161517Q33611314-E5892EE7-B798-4378-961E-EA12A1DF7A95Q33864174-08EFE8BA-8749-4DCD-AA95-BA882CD2BCCEQ33874621-588F0E36-0CFE-4186-AAA6-0D4A1249297DQ33892756-C2A348A3-D028-44EE-A1FF-546B6F7C41EBQ33896844-CABC2DA0-7E94-40E3-9DA7-472E987669B7Q34048144-F1AFDF08-BDAC-49C3-9FB3-78803FC50554Q34296476-3162B249-A832-4ED3-A1A0-2BA547E13C66Q34483460-C6A3F070-C5A5-4009-8D9D-DC8C55F12847Q34517061-80DE73E0-3FAB-4DAC-975F-B611C437C949Q34550194-4521B4AC-6D04-4A5D-942B-00068D83A230Q34680338-30C16D84-F442-47D5-B864-AFAE9648AEF7Q34734477-13B61F7D-FDFE-416B-8EB3-EDAFF00A7FFCQ34784078-D833214F-EFF9-499B-94B7-7D4508E73CD0Q35082170-6ACBD6C1-DEBB-4ED0-9F67-AB87FD38E4FEQ35195760-1FE6B277-E61F-4286-B147-2ACFA1B56226Q35342121-354BD2FF-193A-42DD-9860-4189D1CB619CQ35627868-EF562687-B4F0-4831-98CB-248066D50F21Q35631181-1ECCBB78-75EC-484F-907A-D3891D90CF21Q35700466-237DC4F1-53A8-4824-9490-522F0E7C023AQ35933373-6CDC0069-A2BD-4111-B725-5AA21EBFCC50Q36054418-CCB3130C-4FC2-4438-8D21-C5273C328C89Q36090650-6F222E1A-38C0-4AD1-98EA-8FB0A7330024Q36142926-D18F6087-4363-4F56-B187-22AF33FACCC0Q36244968-7B78F3C1-7260-4077-8D0F-F260D7FF383AQ36271396-E9B0224A-DA66-4EC4-81DF-54849BB34CA9Q36334470-D5EC6AC2-1933-4AFC-9174-8E548085EED0Q36734663-0F813C28-8795-4309-BA2C-18822A14D80EQ36752829-06BDEE58-11F8-4741-B254-FE10C0677EBCQ36847243-8F877AF9-CF6B-449D-95EF-C8704D27DD57
P50
description
cancer researcher
@en
investigadora de cancer
@es
wetenschapper
@nl
name
Jennifer A. Pietenpol
@en
Jennifer A. Pietenpol
@es
Jennifer A. Pietenpol
@nl
type
label
Jennifer A. Pietenpol
@en
Jennifer A. Pietenpol
@es
Jennifer A. Pietenpol
@nl
altLabel
JA Pietenpol
@en
Jennifer A Pietenpol
@en
prefLabel
Jennifer A. Pietenpol
@en
Jennifer A. Pietenpol
@es
Jennifer A. Pietenpol
@nl
P101
P108
P21
P31
P496
0000-0001-6268-6798